Search Result
Results for "
CGT
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-146245
-
-
-
- HY-146244
-
|
ODN 2006; PF-3512676; CpG 7909; ODN 7909
|
Toll-like Receptor (TLR)
Bacterial
NO Synthase
Apoptosis
|
Infection
Cancer
|
|
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .
|
-
-
- HY-150724
-
|
1018 ISS
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .
|
-
-
- HY-150218
-
|
ODN 2006 sodium; ODN 7909 sodium; PF-3512676 sodium; CpG 7909 sodium
|
Toll-like Receptor (TLR)
|
Cancer
|
|
Agatolimod sodium (ODN 2006) is a class B CpG ODN and is a TLR9 agonist. Agatolimod sodium can be used as vaccine adjuvant. Agatolimod sodium can be used for the research of cancer. Sequence: 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’ .
|
-
-
- HY-150743
-
|
|
Toll-like Receptor (TLR)
|
Infection
Inflammation/Immunology
|
|
ODN 2395 is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 is also a TLR9 agonist. ODN 2395 can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' (Note: The bases are phosphorothioate; ODN 2395 contains the partial palindromic sequence cggcgc:gcgccg) .
|
-
-
- HY-145557
-
|
CGT9486; PLX 9486
|
c-Kit
|
Cancer
|
|
Bezuclastinib (CGT9486) is an orally active, highly selective tyrosine kinase inhibitor with potent activity against KIT D816V. Bezuclastinib can be used for the research of nonadvanced systemic mastocytosis (NonAdvSM) .
|
-
-
- HY-109528
-
|
ISIS-2922 sodium
|
CMV
|
Infection
|
|
Fomivirsen (ISIS-2922) sodium is an antisense 21 mer phosphorothioate oligonucleotide. Fomivirsen sodium is an antiviral agent that is used cytomegalovirus retinitis (CMV) research, incluiding in AIDs. Fomivirsen sodium binds to and degrades the mRNAs encoding CMV immediate-early 2 protein, thus inhibiting virus proliferation .
|
-
-
- HY-150741
-
|
|
Toll-like Receptor (TLR)
IFNAR
Interleukin Related
|
Infection
Inflammation/Immunology
Cancer
|
|
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
|
-
-
- HY-150725
-
|
|
IFNAR
TNF Receptor
|
Infection
Inflammation/Immunology
Cancer
|
|
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .
|
-
-
- HY-150750
-
-
-
- HY-150217
-
|
ODN 10101
|
Toll-like Receptor (TLR)
|
Infection
Inflammation/Immunology
|
|
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .
|
-
-
- HY-115625
-
|
|
Progesterone Receptor
Apoptosis
Glycosyltransferase
|
Cancer
|
|
AG-205 is a progesterone receptor membrane component 1 (PGRMC1) antagonist and CGT inhibitor, with an IC50 of 50 μM against rat CGT. AG-205 exhibits antimitotic, antimigratory and anti-invasive activities. AG-205 increases the expression of genes encoding cholesterol biosynthesis pathway or steroidogenic enzymes. AG-205 promotes the regulation of cell cycle by apoptosis and reduces the migratory and invasive capacities of ovarian and breast cancer cells. AG-205 can be used in research related to renal cancer and breast cancer .
|
-
-
- HY-150726
-
|
|
Toll-like Receptor (TLR)
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .
|
-
-
- HY-W073524
-
|
|
Fluorescent Dye
|
Others
|
|
DFAME is a red fluorophore (Ex = 508 nm, Em = 641 nm). DFAME binds to Beetroot and Corn (dimeric fluorescent RNA aptamers) to form Beetroot-DFAME (Kd = 460 nM) and Corn-DFAME (Kd = 3600 nM). Beetroot-DFAME and Corn-DFAME can be used to form RNA assemblies in living cells. Creating RNA assemblies can be used for the study of RNA Nanostructures. DNA/RNA Nanostructures would be useful in cell and gene therapy (CGT) research .
|
-
-
- HY-148511
-
|
CMP-001
|
Toll-like Receptor (TLR)
IFNAR
PD-1/PD-L1
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
|
-
-
- HY-148190
-
|
CGT-8012
|
Dipeptidyl Peptidase
|
Endocrinology
|
|
Sheng Gelieting (CGT-8012) is a dipeptidy peptidase-IV enzyme (DP-IV) inhibitor. Sheng Gelieting has great DP-IV inhibition activity with an IC50 value of 87 nM. Sheng Gelieting can be used for curing or preventing diseases relevant to the dipeptidy peptidase-IV enzyme, such as the diabetes, particularly the II-type diabete .
|
-
-
- HY-150747
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
ODN 6016 is a CpG-A oligonucleotides. ODN 6016 can induce IFN-α production, can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G .
|
-
-
- HY-145728
-
|
ISIS-2302
|
Integrin
|
Inflammation/Immunology
|
|
Alicaforsen is an oligonucleotide and immunostimulant targeting human ICAM-1 mRNA. Alicaforsen hybridizes to specific sites to reduce the expression level of ICAM-1. Alicaforsen is applicable to relevant research on psoriasis, rheumatoid arthritis and inflammatory bowel disease .
|
-
-
- HY-150734
-
|
|
Toll-like Receptor (TLR)
|
Infection
Inflammation/Immunology
|
|
ODN 2007, a class B CpG ODN (oligodeoxynucleotide), is a Toll-like receptor (TLR) ligand. ODN 2007 can be used as an immunomodulator, vaccine adjuvant, and enhance immune responses in mammals, fish, and humans. ODN 2007 sequence: 5'-TCGTCGTTGTCGTTTTGTCGTT-3' .
|
-
-
- HY-150742
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent TLR9 agonist. ODN 2336 induces the production of IFN-α. ODN 2336 up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines .
|
-
-
- HY-118874
-
|
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research .
|
-
-
- HY-177627
-
-
-
- HY-177627A
-
|
CGT 003 sodium
|
Early 2 Factor (E2F)
|
Inflammation/Immunology
|
|
Edifoligide sodium is a decoy oligonucleotide that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure
|
-
-
- HY-150748
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
Cancer
|
|
ODN D-SL01, a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. ODN D-SL01 has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .
|
-
-
- HY-RS15443
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
UGT8 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
UGT8 Human Pre-designed siRNA Set A
UGT8 Human Pre-designed siRNA Set A
-
- HY-150213
-
|
|
CDK
|
Inflammation/Immunology
|
|
ODN BW001 is an oligodeoxynucleotide (ODN). ODN BW001 plays a regulatory role in the proliferation and activation of osteoblast .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W073524
-
|
|
Fluorescent Dyes
|
|
DFAME is a red fluorophore (Ex = 508 nm, Em = 641 nm). DFAME binds to Beetroot and Corn (dimeric fluorescent RNA aptamers) to form Beetroot-DFAME (Kd = 460 nM) and Corn-DFAME (Kd = 3600 nM). Beetroot-DFAME and Corn-DFAME can be used to form RNA assemblies in living cells. Creating RNA assemblies can be used for the study of RNA Nanostructures. DNA/RNA Nanostructures would be useful in cell and gene therapy (CGT) research .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-146245
-
ODN 1826
Maximum Cited Publications
10 Publications Verification
CpG 1826
|
|
CpG ODNs
|
|
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .
|
-
- HY-146244
-
|
ODN 2006; PF-3512676; CpG 7909; ODN 7909
|
|
CpG ODNs
|
|
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .
|
-
- HY-150724
-
|
1018 ISS
|
|
CpG ODNs
|
|
ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .
|
-
- HY-150218
-
|
ODN 2006 sodium; ODN 7909 sodium; PF-3512676 sodium; CpG 7909 sodium
|
|
CpG ODNs
|
|
Agatolimod sodium (ODN 2006) is a class B CpG ODN and is a TLR9 agonist. Agatolimod sodium can be used as vaccine adjuvant. Agatolimod sodium can be used for the research of cancer. Sequence: 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’ .
|
-
- HY-150743
-
|
|
|
CpG ODNs
|
|
ODN 2395 is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 is also a TLR9 agonist. ODN 2395 can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' (Note: The bases are phosphorothioate; ODN 2395 contains the partial palindromic sequence cggcgc:gcgccg) .
|
-
- HY-109528
-
|
ISIS-2922 sodium
|
|
Antisense Oligonucleotides
|
|
Fomivirsen (ISIS-2922) sodium is an antisense 21 mer phosphorothioate oligonucleotide. Fomivirsen sodium is an antiviral agent that is used cytomegalovirus retinitis (CMV) research, incluiding in AIDs. Fomivirsen sodium binds to and degrades the mRNAs encoding CMV immediate-early 2 protein, thus inhibiting virus proliferation .
|
-
- HY-150741
-
|
|
|
CpG ODNs
|
|
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
|
-
- HY-150725
-
|
|
|
CpG ODNs
|
|
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .
|
-
- HY-150750
-
|
|
|
CpG ODNs
|
|
ODN M362, a class C oligodeoxynucleotide, is a TLR-9 agonist and can be used as a vaccine adjuvant. ODN M362 induces cancer cell apoptosis .
|
-
- HY-150217
-
|
ODN 10101
|
|
CpG ODNs
|
|
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .
|
-
- HY-150726
-
|
|
|
CpG ODNs
|
|
ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .
|
-
- HY-148511
-
|
CMP-001
|
|
CpG ODNs
|
|
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
|
-
- HY-150747
-
|
|
|
CpG ODNs
|
|
ODN 6016 is a CpG-A oligonucleotides. ODN 6016 can induce IFN-α production, can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G .
|
-
- HY-145728
-
|
ISIS-2302
|
|
Antisense Oligonucleotides
|
|
Alicaforsen is an oligonucleotide and immunostimulant targeting human ICAM-1 mRNA. Alicaforsen hybridizes to specific sites to reduce the expression level of ICAM-1. Alicaforsen is applicable to relevant research on psoriasis, rheumatoid arthritis and inflammatory bowel disease .
|
-
- HY-150734
-
|
|
|
CpG ODNs
|
|
ODN 2007, a class B CpG ODN (oligodeoxynucleotide), is a Toll-like receptor (TLR) ligand. ODN 2007 can be used as an immunomodulator, vaccine adjuvant, and enhance immune responses in mammals, fish, and humans. ODN 2007 sequence: 5'-TCGTCGTTGTCGTTTTGTCGTT-3' .
|
-
- HY-150742
-
|
|
|
CpG ODNs
|
|
ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent TLR9 agonist. ODN 2336 induces the production of IFN-α. ODN 2336 up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines .
|
-
- HY-118874
-
|
|
|
Antisense Oligonucleotides
|
|
Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research .
|
-
- HY-177627
-
|
CGT 003
|
|
Decoy ODNs
|
|
Edifoligide is a decoy oligonucleotide that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure
|
-
- HY-177627A
-
|
CGT 003 sodium
|
|
Decoy ODNs
|
|
Edifoligide sodium is a decoy oligonucleotide that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure
|
-
- HY-150748
-
|
|
|
CpG ODNs
|
|
ODN D-SL01, a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. ODN D-SL01 has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .
|
-
- HY-RS15443
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
UGT8 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-150213
-
|
|
|
CpG ODNs
|
|
ODN BW001 is an oligodeoxynucleotide (ODN). ODN BW001 plays a regulatory role in the proliferation and activation of osteoblast .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: